ID | 67498 |
フルテキストURL | |
著者 |
Yoshida, Saori
Preliminary Examination Room, Okayama University Hospital
Kawai, Hotaka
Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Soe, Yamin
Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Eain, Htoo Shwe
Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Sanou, Sho
Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Takabatake, Kiyofumi
Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
publons
researchmap
Takeshita, Yohei
Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Hisatomi, Miki
Department of Oral and Maxillofacial Radiology, Okayama University Hospital
Kaken ID
publons
researchmap
Nagatsuka, Hitoshi
Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
publons
researchmap
Asaumi, Junichi
Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Yanagi, Yoshinobu
Preliminary Examination Room, Okayama University Hospital
|
抄録 | Cisplatin is a platinum-based compound that is widely used for treating inoperable oral squamous cell carcinoma (OSCC) in Japan; however, resistance to cisplatin presents a challenge and innovative approaches are required. We aimed to investigate the therapeutic potential of targeting the chemokine receptor CXCR4, which is involved in angiogenesis and tumor progression, using the CXCR4 inhibitor AMD3100, in combination with cisplatin. AMD3100 induced necrosis and bleeding in OSCC xenografts by inhibiting angiogenesis. We investigated the combined ability of AMD3100 plus cisplatin to enhance the antitumor effect in cisplatin-resistant OSCC. An MTS assay identified HSC-2 cells as cisplatin-resistant cells in vitro. Mice treated with the cisplatin-AMD combination exhibited the most significant reduction in tumor volume, accompanied by extensive hemorrhage and necrosis. Histological examination indicated thin and short tumor vessels in the AMD and cisplatin–AMD groups. These results indicated that cisplatin and AMD3100 had synergistic antitumor effects, highlighting their potential for vascular therapy of refractory OSCC. Antitumor vascular therapy using cisplatin combined with a CXCR4 inhibitor provides a novel strategy for addressing cisplatin-resistant OSCC.
|
キーワード | oral squamous cell carcinoma
CXCR4
cisplatin
antitumor vascular therapy
|
発行日 | 2024-06-25
|
出版物タイトル |
Cancers
|
巻 | 16巻
|
号 | 13号
|
出版者 | MDPI
|
開始ページ | 2326
|
ISSN | 2072-6694
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2024 by the authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.3390/cancers16132326
|
ライセンス | https://creativecommons.org/licenses/by/4.0/
|
Citation | Yoshida, S.; Kawai, H.; Soe, Y.; Eain, H.S.; Sanou, S.; Takabatake, K.; Takeshita, Y.; Hisatomi, M.; Nagatsuka, H.; Asaumi, J.; et al. Efficacy of Cisplatin–CXCR4 Antagonist Combination Therapy in Oral Cancer. Cancers 2024, 16, 2326. https://doi.org/10.3390/cancers16132326
|
助成機関名 |
Japan Society for the Promotion of Science
|
助成番号 | 19K19160
20H03888
23K09332
20K10178
23K09080
21K10043
22K10170
1K17089
23K16149
24K1313006
22KK027505
|